Literature DB >> 20514285

Anterograde versus retrograde techniques: Can we use surgical margin status as a quality indicator?

D Robert Siemens1.   

Abstract

Year:  2010        PMID： 20514285      PMCID： PMC2874596          DOI： 10.5489/cuaj.852

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  7 in total

Review 1.  Development of prostate cancer quality indicators: a modified Delphi approach.

Authors:  Anna R Gagliardi; Neil Fleshner; Bernard Langer; Hartley Stern; Adalsteinn D Brown
Journal:  Can J Urol       Date:  2005-10       Impact factor: 1.344

2.  Validation of quality indicators for radical prostatectomy.

Authors:  Ellen O M Chan; Patti A Groome; D Robert Siemens
Journal:  Int J Cancer       Date:  2008-12-01       Impact factor: 7.396

3.  The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer.

Authors:  André N Vis; Fritz H Schröder; Theodorus H van der Kwast
Journal:  Eur Urol       Date:  2006-01-06       Impact factor: 20.096

4.  Measuring the quality of care for localized prostate cancer.

Authors:  David C Miller; James E Montie; John T Wei
Journal:  J Urol       Date:  2005-08       Impact factor: 7.450

5.  Randomized trial comparing an anterograde versus a retrograde approach to open radical prostatectomy: results in terms of positive margin rate.

Authors:  Alessandro Sciarra; Cristiano Cristini; Magnus Von Heland; Stefano Salciccia; Vincenzo Gentile
Journal:  Can Urol Assoc J       Date:  2010-06       Impact factor: 1.862

6.  Quality-of-care indicators for early-stage prostate cancer.

Authors:  Benjamin A Spencer; Michael Steinberg; Jennifer Malin; John Adams; Mark S Litwin
Journal:  J Clin Oncol       Date:  2003-05-15       Impact factor: 44.544

7.  Impact of positive surgical margins after radical prostatectomy differs by disease risk group.

Authors:  Sultan Alkhateeb; Shabbir Alibhai; Neil Fleshner; Antonio Finelli; Michael Jewett; Alexandre Zlotta; Michael Nesbitt; Gina Lockwood; John Trachtenberg
Journal:  J Urol       Date:  2010-01       Impact factor: 7.450
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.